-
Q&A and Panel Discussion
6:40
-
Update on treatment of unresectable stage III NSCLC_Jeff Bradley, MD, FACR, FASTRO; #DDHO2021
1:18
-
Uncommon and emerging targets for NSCLC_Fadlo Khuri, MD; #DDHO2021
2:39
-
Andreas N. Saltos, MD; Moffitt Cancer Center; 5Live; #IASLC21
13:27
-
Narjust Duma, MD; University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center; 5Live; #IASLC21
5:10
-
Benjamin Besse, MD, PhD; Gustave Roussy Cancer Campus; 5Live; #IASLC21
6:36
-
Suresh Ramalingam, MD, FACP, FASCO; Winship Cancer Institute of Emory University; 5Live; #IASLC21
9:26
-
David Carbone, MD, PhD, FASCO; The Ohio State University Comprehensive Cancer Center; 5Live; #IASLC21
6:56
-
Suresh Ramalingam, MD, FASCO; Winship Cancer Institute Emory University 5Live #ASCO20
5:27
Key insights on Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
-
Vivek Subbiah, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO20
6:47
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
-
Roy Herbst, MD, PhD, FACP, FASCO; Yale Cancer Center 5Live #ASCO20
4:24
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company